N/A N=37 PREVAIL VII: Cataract Surgery in Ebola Survivors
Cataract
Primary: Proportion of EVD Survivors With Evidence of Persistence of Ebola Viral RNA in Ocular Tissue — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,500 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
Ebola Virus
Primary: Serious Adverse Events. — 6; 6; 8 Participants — p=0.68
Phase 2 N=38 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Ebola
Primary: Mean Assay Negativity Rate (ANR) for Ebola Virus During the Treatment Phase — 0.85; 0.76 proportion of semen samples
Phase 2 N=72 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Ebola Virus Infection
Primary: Mortality — 13; 8 Participants
Phase 3 N=680 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
Ebola Virus
Primary: Mortality — 93; 61; 52; 84 deaths
Phase 3 N=8,651 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)
Hemorrhagic Fever, Ebola
Primary: Laboratory-confirmed Ebola (Study Diagnostics) — 0; 0 Participants
Phase 1 N=513 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
Ebola Virus
Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants
Phase 1 N=40 Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination
Ebola Virus Disease
Primary: Safety and Tolerability of Administration of ChAd3-EBO Z and MVA-EBO Z 7 Days Later. This Will be Done by Recording the Number of Participants Who Experience Adverse…
Phase 1 N=19 Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Healthy Adult Immune Responses to Vaccine
Primary: Number of Subjects Experiencing Infusion Reaction During Product Administration — 0; 0; 0; 3 Participants
Phase 3 N=606 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
Hemorrhagic Fever, Ebola
Primary: Survival at Day 14 After Start of Intervention — 58; 260 Participants
Phase 1 N=39 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Phase 2 N=251 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Ebola
Primary: Number of Participants With Solicited Adverse Events Following V920 Vaccination — 5; 1; 2; 1 Participants
Phase 1 N=40 Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
Phase 1 N=39 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)
Ebola Virus
Primary: Number of Participants With One or More Solicited Local Treatment-Emergent Adverse Events (TEAE) — 8; 8; 10; 3 Participants
Phase 2 N=3,013 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults
Virus Diseases
Primary: Number of Subjects With Solicited Local Adverse Events — 356; 57; 3; 0 Participants